Lab21 is expanding its clinical diagnostics portfolio with the introduction of a new service to identify the two most common causes of fungal pneumonia. The CE-marked FXGTM:RESP (ASP+) test, developed by UK diagnostics company Myconostica, will identify infections caused by Aspergillus and Pneumocystis, which account for over 95% of cases of fungal pneumonia and could radically alter the diagnosis of fungal disease.
Epredia was established in July 2019 through the acquisition by PHC Group of the Anatomical Pathology division of Thermo Fisher Scientific. Our name has changed, however as a standalone business our mission remains the same: to improve lives by enhancing cancer diagnostics.
We are powered by the quality brands you know and trust, such as...
10 Union Street, London, SE1 1SZ
2 March, 2026
Online
3-4 March, 2026
Hinxton Hall Conference Centre, Wellcome Genome Campus, Hinxton, CB10 1RQ
9-10 March, 2026
Online
10-11 March, 2026
Henry B. González Convention Center, San Antonio, Texas, USA
21-26 March, 2026
